Polymers for delivery of factor VIII and/or factor IX
View Patent ↗In some aspects, a composition comprising a pH-sensitive crosslinked copolymer of methacrylic acid and poly(ethylene glycol) monomethyl ether methacrylate and a therapeutic protein is provided. In some embodiments, the therapeutic protein is a high molecular weight protein such as factor VIII or factor IX. In some embodiments, the composition is orally administered to a patient to treat a disease or disorder such as, e.g., hemophilia.
1. A composition comprising:
(A) a therapeutic protein; wherein the therapeutic protein is factor IX or factor VIII; and
(B1) a copolymer comprising methacrylic acid and poly(ethylene glycol) monomethyl ether monomethacrylate crosslinked with about 0.8-1.0% poly(ethylene glycol) dimethacrylate (PEGDMA) wherein the poly(ethylene glycol) component of the PEGDMA has an average molecular weight of about 300-500.
2. The composition of claim 1 , wherein the therapeutic protein is factor IX.
3. The composition of claim 1 , wherein the therapeutic protein is factor VIII.
4. The composition of claim 1 , wherein the composition is comprised in a pharmaceutical preparation formulated for oral administration.
5. The composition of claim 1 , wherein the ratio of the molar percentage of methacrylic acid (MAA) to poly(ethylene glycol) monomethyl ether monomethacrylate is from about 1:1 to about 60:1.
6. The composition of claim 5 , wherein the ratio of the molar percentage of methacrylic acid to poly(ethylene glycol) monomethyl ether monomethacrylate is from about 20:1 to about 40:1.
7. The composition of claim 1 , wherein the copolymer comprises from about 90 mol % to about 99 mol % methacrylic acid.
8. The composition of claim 7 , wherein the copolymer comprises from about 96.5 mol % to about 97.5 mol % methacrylic acid.
9. The composition of claim 1 , wherein the copolymer comprises from about 1 mol % to about 10 mol % poly(ethylene glycol) monomethyl ether monomethacrylate.
10. The composition of claim 9 , wherein the copolymer comprises from about 2.5 mol % to about 3.5 mol % poly(ethylene glycol) monomethyl ether monomethacrylate.
11. The composition of claim 1 , wherein the composition comprises greater than about 20 μg of therapeutic protein per mg of copolymer.
12. The composition of claim 11 , wherein the composition comprises greater than about 30 μg of therapeutic protein per mg of copolymer.
13. The composition of claim 1 , wherein the copolymer has a particle size less than 100 μm.
14. The composition of claim 13 , wherein the particle size is less than 50 μm.
15. The composition of claim 1 , wherein the copolymer swelling increases at a pH greater than about 5.
16. The composition of claim 1 , wherein the composition releases greater than about 0.1 μg of therapeutic protein per mg of copolymer at pH 7.4.
17. The composition of claim 16 , wherein the composition releases greater than about 0.25 μg of therapeutic protein per mg of copolymer at pH 7.4.
18. The composition of claim 1 , wherein the therapeutic protein is factor VIII or IX and further comprises a targeting compound selected from an antibody, lectin, protein, or small molecule.
19. The composition of claim 18 , wherein the targeting compound promotes bioadhesion.
20. The composition of claim 18 , wherein the targeting compound is a lectin.
21. The composition of claim 20 , wherein the lectin is wheat germ agglutinin.
22. A method of treating hemophilia in a patient comprising orally administering a pharmacologically effective amount of the composition of claim 1 to a patient in need of such treatment.